Fast-growing KSQ and David Meeker fuel up with a hefty $80M round on the way to first human studies
KSQ is all about fast, controlled speed.
Over the past year — with a $76 million launch round to bank on — it’s roughly doubled the staff to 70 and brought in a big crew of CRO workers to assist in building a platform and a pipeline that’s been rapidly lining up preclinical drug candidates.
The crew, led by ex-Sanofi Genzyme chief David Meeker, has used CRISPR/Cas9 tech to screen for a lineup of disease-relevant genes. And it’s identified a lead preclinical candidate in a slate of new programs that Meeker and his team believes can hit a more effective target than PD-1 so they can make an adoptive T cell candidate for fighting PD-1 resistant cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
